俱乐部电话：0536-8237601(秘书处）、0536—8237608（企业服务）、0536—8237609（经济合作） 企业简介 潍坊吉涛医学科技有限公司是潍坊市重点引进人才创办的科技型企业，由中科院博士后、泰山产业领军 人才刘天津研究员与奎文区政府国有企业恒建集团联合成立，是省重点人才工程项目实施单位。公司聚 焦于免疫细胞、干细胞治疗技术的开发，以及癌症早期诊断、早期干预新技术的开发及应用，开发了基 于 ctDNA 甲基化检测的肿瘤早期诊断平台，及用于精准治疗的免疫细胞、干细胞的存储和细胞制备平 台，具备一流的研发团队，是山东省认定的首批省级新型研发机构，获批潍坊市细胞存储与制备技术重 点实验室、潍坊市大肠癌早期诊断技术重点实验室，吉涛医学的大肠癌早筛项目曾荣获国家级创新创业 大赛全国总决赛一等奖。 潍坊市（吉涛）区域细胞组织库及细胞制备中心位于奎文区核心地段，由政府相关部门批准，吉涛医学 投资建设，总投资额2000余万元，包含公益性生命科普馆和1200平方米的细胞存储库及制备中心组成， 项目引进国际尖端的储存、制备和研发设备，采用国际标准的区域细胞组织库及细胞制备中心的细胞生 产和存储管理模式，遵照国 ...

Core Viewpoint - The "Development Plan for the Open Innovation of the Biopharmaceutical Industry Chain in China (Jiangsu) Free Trade Zone" aims to enhance the biopharmaceutical industry's innovation capabilities and modernize its supply chain by 2030, with a focus on key areas such as large molecule biopharmaceuticals, cell and gene therapy, and innovative medical devices [1][2]. Group 1: Key Tasks and Goals - The plan outlines 18 key tasks across seven areas, including enhancing R&D innovation, improving product approval services, and strengthening supply chain systems [1][2]. - By 2030, the goal is to achieve rapid growth in the biopharmaceutical industry scale, optimize the innovation ecosystem, and significantly improve the level of openness and safety assurance capabilities [1][2]. Group 2: Industry Performance and Contribution - In 2024, Jiangsu's biopharmaceutical cluster is projected to generate revenues of 454.39 billion yuan and a profit of 73.04 billion yuan, accounting for 15.1% and 17.9% of the national totals, respectively, making it the leading province in China [2]. - The biopharmaceutical industry within the Jiangsu Free Trade Zone is expected to contribute approximately half of the province's total biopharmaceutical output [2]. Group 3: R&D and Innovation Measures - The plan emphasizes the application of big data and artificial intelligence in drug target screening, molecular design, and medical device manufacturing [2][3]. - It encourages clinical research in advanced treatment methods such as immunotherapy, stem cell therapy, and gene therapy, while supporting the establishment of national and industry standards [2][3]. Group 4: Production and Regulatory Framework - The plan proposes pilot projects for segmented production of chemical raw materials and biological products, as well as reforms in the supervision of imported experimental animals [3]. - It aims to enhance the convenience of customs clearance for medical and research materials, thereby improving the R&D and production environment for companies [3]. Group 5: Financial Support and Investment - The plan includes measures to support biopharmaceutical companies in listing on various stock exchanges and encourages the establishment of investment funds focused on the biopharmaceutical sector [4]. - It also addresses cross-border data flow issues by proposing a negative list for data export in the biopharmaceutical field, which is crucial for foreign investment [4][5].